Advertisement
UK markets close in 1 hour 27 minutes
  • FTSE 100

    8,325.80
    +112.31 (+1.37%)
     
  • FTSE 250

    20,390.42
    +225.88 (+1.12%)
     
  • AIM

    776.87
    +5.34 (+0.69%)
     
  • GBP/EUR

    1.1647
    -0.0012 (-0.10%)
     
  • GBP/USD

    1.2558
    -0.0006 (-0.05%)
     
  • Bitcoin GBP

    50,343.93
    -541.91 (-1.06%)
     
  • CMC Crypto 200

    1,317.38
    -47.75 (-3.50%)
     
  • S&P 500

    5,187.38
    +6.64 (+0.13%)
     
  • DOW

    38,930.69
    +78.42 (+0.20%)
     
  • CRUDE OIL

    78.10
    -0.38 (-0.48%)
     
  • GOLD FUTURES

    2,328.00
    -3.20 (-0.14%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • DAX

    18,374.00
    +198.79 (+1.09%)
     
  • CAC 40

    8,060.22
    +63.58 (+0.80%)
     

Revvity to Present at BofA Securities 2024 Health Care Conference

WALTHAM, Mass., April 25, 2024--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV.

Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its strategic priorities. To register, click here.

A live audio webcast will be available on the Events section of the Company’s website at www.revvity.com. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days.

ADVERTISEMENT

About Revvity
At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240425504435/en/

Contacts

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Media Relations:
Chet Murray
(781) 663-5719
chet.murray@revvity.com